Alzheimer’s and Parkinson’s biotech AltPep raises $52.9M Series B

Seattle-based biotech company AltPep has raised $52.9 million in a Series B round. The funding follows previous investments of $44.4 million in 2022 and $23 million in 2021.

Founded in 2019, AltPep specializes in amyloid diseases such as Alzheimer’s and Parkinson’s. The new funding will help the company secure FDA approval for a diagnostic. Moving forward, AltPep also hopes to launch clinical trials for one of its treatments.

“This new funding bolsters our efforts to bring early detection and treatment to patients with Alzheimer’s and Parkinson’s diseases,” said Valerie Daggett, the company’s founder and CEO. “We are thrilled to have the support of our former and new investors.”

READ THE STORY at Puget Sound Business Journal »